Dr. Ayman Elguindy is a globally recognized leader in the EBV field. Before founding AbVir, he served as Chief Scientific Officer at Viracta Therapeutics and held an Associate Professor position at Yale University. Dr. Elguindy sits on the governing board of the International EBV Research Association and has led multi-national collaborations to unravel EBV's role in disease. He brings a visionary approach to oncology and oncogenic virus research, with deep expertise in translating science into clinical applications. His work in developing EBV-targeted therapies, forming impactful collaborations, and successfully managing regulatory, IP, and fundraising initiatives has driven innovation and organizational growth. As an American Cancer Society Research Scholar and former academic leader, Dr. Elguindy remains committed to patient-centered research and bringing novel therapies to patients.